Seeking Alpha

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®

– Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – “We are pleased to highlight ...
Fierce Biotech

Gilead turns down chance to build on Assembly's phase 1-stage HBV antiviral

Gilead has handed back a next-gen hepatitis B antiviral to Assembly Biosciences, while the two companies continue to partner ...
Seeking Alpha

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean plasma HBV DNA reductions of 3.2 ...
BioWorld

Items Tagged with 'capsid assembly modulators'

Current therapies for chronic hepatitis B virus (HBV) infection can effectively suppress viral replication but do not achieve a functional or complete cure. Capsid assembly modulators inhibit the ...
Science Daily

Self-assembly of a large metal-peptide capsid nanostructure through geometric control

A significant advancement in molecular engineering has produced a large, hollow spherical shell nanostructure through the self-assembly of peptides and metal ions, report researchers from Japan. This ...
Nasdaq

Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic ...

– Phase 1b study will evaluate safety, pharmacokinetic and efficacy endpoints in participants with chronic hepatitis B virus infection with interim data expected by the end of 2024 – SOUTH SAN ...
Nasdaq

New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 ...

– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection ...
Insider Monkey

Assembly Bio’s (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial

Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the growth stocks that could double by 2027. On June 25, the company announced positive topline results from its Phase 1b trial of ABI-4334, a capsid ...
BioWorld

Discovery of TBA derivatives as potent HBV capsid assembly modulators

Researchers from Weifang Medical University and affiliated organizations have published details on the discovery of novel hepatitis B virus (HBV) capsid assembly modulators (CAMs).
Nature

RNA Virus Structure and Self-Assembly

RNA viruses are renowned for their elegant structure and finely tuned self‐assembly processes, which are critical both for viral life cycles and for potential applications in nanotechnology and ...
Business Insider

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed – – In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity ...